Report No. 3/2026 Admission and conditional introduction of the Company’s ordinary bearer shares of series O to trading on the WSE Main Market

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”), hereby announces that today it became aware that on 9 January 2026 the Management Board of the Warsaw Stock Exchange S.A. (the “WSE”) adopted Resolution No. 18/2026 on the admission and introduction to exchange trading on the WSE Main […]

Report No. 2/2026 Conditional registration of the Company’s ordinary bearer shares of series O in the securities depository maintained by KDPW S.A.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”), hereby announces that on 7 January 2026 the National Depository for Securities S.A. (Krajowy Depozyt Papierów Wartościowych S.A., “KDPW”) issued Statement No. 8/2026 regarding the conclusion with the Company of an agreement on the registration in the securities depository […]

Report No. 1/2026 Schedule of publication of periodic reports in 2026

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Issuer”), hereby announces that the Issuer’s periodic reports in 2026 will be published on the following dates: annual report for the financial year 2025 – 28 April 2026; quarterly report for Q1 2026 – 29 May 2026; semi-annual report for […]

Bioceltix SA shareholders have approved the share issue. The company plans to raise approximately PLN 45 million for the construction of a new stem cell facility.

Bioceltix, a publicly traded biotechnology company with a veterinary profile, received shareholder support for an issue of up to 457,000 shares during its Extraordinary General Meeting. The company plans to raise approximately PLN 45 million, which will allow it to complete the construction of a large-scale pharmaceutical production facility and secure its financial position for […]

Puls Biznesu: Funding needed for dog medications. Bioceltix seeks capital again

Dr. Paweł Wielgus, Eng., spoke with Puls Biznesu about current plans to raise capital for the construction of a new plant and summarized the company’s current developments. “We are working on responses to EMA inquiries; the deadline for submitting them is the end of the year. We are re-validating the technological route, and an inspection […]

Bioceltix SA announces the success of a clinical trial of a product for atopic dermatitis in dogs. The company is one step closer to registering a breakthrough drug.

A veterinary biotech company listed on the Warsaw Stock Exchange (GPW) has published the final results of a clinical trial of BCX-CM-AD for atopic dermatitis (AD) in dogs. These confirm the safety and effectiveness of Bioceltix’s cell therapy in the short, medium, and long term. A single administration of the drug significantly alleviated skin lesions […]

Two medicines with EMA, grant awarded, webinar

Good morning, the latest report from GlobalPETS shows that we are not cutting back on the health and wellbeing of our pets. Supplements, functional diets and innovative veterinary treatments are generating growing demand worldwide. Biological therapies for companion animals are very much our specialty. And dogs? They may soon see a breakthrough drug for osteoarthritis! […]

Telewizja Biznesowa: Bioceltix – from a startup to a million-dollar company

During the Wall Street in Karpacz, Dr. Paweł Wielgus, Eng., spoke with Telewizja Biznesowa about our journey from idea to commercialization. We went back a decade to reminisce about our first PowerPoint presentation and the determination with which we convinced investors that veterinary medicine deserved a breakthrough, and that we had a plan for it. […]

Parkiet.com: Pessimism around biotechnology is absurdly high. Will the tide turn?

This is an important time for Polish biotechnology. Despite geopolitical turmoil, many companies are increasingly close to breakthroughs and commercialization of their projects. We believe that the successful registration process of BCX-CM-J for canine osteoarthritis and BCX-EM for equine arthritis will pave the way for further innovations from Poland. Meanwhile, significant biotechnology projects typically originate […]

Atopic dermatitis drug, dialogue with the EMA, mission to the USA

Good morning, we are on the verge of registering BCX-CM-J for osteoarthritis in dogs. BCX-EM for arthritis in horses has already been submitted to the European Medicines Agency. We have also published preliminary, positive results for the BCX-EM-AD product for canine atopic dermatitis. A fortunate “three” also in the overall ranking of the prestigious Stock […]

Gazeta Wyborcza: Veterinary Medicine. The largest stem cell factory will be created in Wrocław.

Veterinary biotechnology has the potential to revolutionize the current approach to animal treatment, increasing effectiveness and reducing side effects, says Dr. Paweł Wielgus, Eng., in a new interview with Gazeta Wyborcza. We discuss plans related to, among other things, the new plant with representatives of the Wałbrzych Special Economic Zone “Invest-Park,” as our new facility […]

Bioceltix is ​​initiating the registration process for a drug for equine arthritis. The company has submitted an application to the European Medicines Agency.

Another important milestone in the history of Bioceltix. The publicly traded veterinary company has submitted an application to the European Medicines Agency (EMA) for a positive recommendation for the stem cell-based drug BCX-EM for equine arthritis. The excellent results from the product’s clinical trial confirmed its efficacy and safety. The drug’s therapeutic effect persists even […]

Puls Biznesu: Dog medicines are heating up Bioceltix

Dog medications are heating up Bioceltix, we read in Puls Biznesu. The same goes for the results of this year’s “Listed Company of the Year,” as we mark the 26-year history of the ranking as: Leader in the Success category in 2024, Leader in the Development Prospects category, and 3rd place overall (tied with Vercom […]

A new year, the same consistency!

Good morning! This will be a favorable year for us in many respects. Thanks to the achievement of last year’s goals, we are maintaining strong momentum toward the commercialization of innovative therapies for animals. “Consistency” is also a key word for 2025, as we have scheduled breakthrough events in the Bioceltix calendar. We are also […]

Bioceltix announces success in clinical trial of equine arthritis product. Company one step closer to registration and commercialization of breakthrough drug

A veterinary biotechnology company listed on the Warsaw Stock Exchange (GPW) has published the full results of a clinical trial of a product for equine arthritis. They confirm the efficacy and safety of the pioneering technology using mesenchymal stem cells. The results indicate that the therapeutic effect of a single dose of BCX-EM was achieved […]

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.